Whole genome methylation analyses of schizophrenia patients before and after treatment

Figures & data

Table 1. Number of DMRs in the female groups.

Female patients compared to female pool of healthy controls
	Complete remission			Incomplete remission
Patient (no.)	1	2	3	4	5	6	7	8
DMRs before treatment (n)	608	357	749	1205	359	1184	885	255
DMRs after treatment (n)	1057	479	260	1155	902	1155	354	753

Table 2. Number of DMRs in the male groups.

Male patients compared to male pool of healthy controls
	Complete remission			Incomplete remission
Patient (no.)	1	2	3	4	5	6	7	8	9	10	11	12
DMRs before treatment (n)	534	467	455	496	726	1648	747	502	521	625	387	666
DMRs after treatment (n)	555	934	397	827	576	1252	628	754	537	487	390	1064

Table 3. Number of DMRs that are present in >50% and 100% from the sets in the ‘before’ and ‘after’ treatment groups among the schizophrenia patients.

	Females				Males
	Complete remission		Incomplete remission		Complete remission		Incomplete remission
	DMRs before treatment (n)	DMRs after treatment (n)	DMRs before treatment (n)	DMRs after treatment (n)	DMRs before treatment (n)	DMRs after treatment (n)	DMRs before treatment (n)	DMRs after treatment (n)
>50% of the patients	867	785	627	680	306	293	299	291
100% of the patients	26	16	46	77	56	46	14	11

Table 4. Function of genes with DMRs in female patients in complete remission.

Females in complete remission
Gene name	Gene function	CytoBand	ChrName	Description	CpG	Methylation status
Before treatment
MIR181C	Post-transcriptional regulation	p13.13	chr19	PROMOTER	117/41	Hypermethylated
After treatment
BCOR	Transcriptional corepressor, protein ubiquitination	p11.4	chrX	INSIDE	54/75/168	Hypermethylated

Table 5. Function of genes with DMRs in male patients in complete remission.

Males in complete remission
Gene name	Gene function	CytoBand	ChrName	Description	CpG	Methylation status
Before treatment
C16orf70	Unknown function	q22.1	chr16	PROMOTER	CpG: 44	Hypermethylated
CST3	Inhibitor of cysteine proteinases	p11.21	chr20	INSIDE	CpG: 84	Hypomethylated
DDRGK1	Unknown function	p13	chr20	INSIDE	CpG: 47	Hypermethylated
FA2H	Sphingolipid metabolic process	q23.1	chr16	INSIDE	CpG: 78	Hypomethylated
FLJ30058	Unknown function	q26.1	chrX	INSIDE	CpG: 63	Hypomethylated
MFSD2B	Unknown function	p23.3	chr2	PROMOTER	CpG: 66	Hypomethylated
RFX4	Transcription factor	q23.3	chr12	PROMOTER	CpG: 41	Hypermethylated
UBE2J1	Ubiquitin-mediated proteolysis	q15	chr6	INSIDE	CpG: 103	Hypomethylated
ZNF311	Transcription factor	p22.1	chr6	DOWNSTREAM	CpG: 42	Hypermethylated
After treatment
AP1S3	Intracellular protein transport	q36.1	chr2	INSIDE	CpG: 79	Hypermethylated
C16orf59	Unknown function	p13.3	chr16	PROMOTER	CpG: 67	Hypermethylated
KCNK15	Potassium channel protein	q13.12	chr20	PROMOTER	CpG: 70	Hypomethylated
LOC146336	Unknown function	p13.3	chr16	DOWNSTREAM	CpG: 22	Hypermethylated
MGC16384	Unknown function	q24.33	chr12	PROMOTER	CpG: 88	Hypermethylated
XRN2	RNA metabolism	p11.22	chr20	DOWNSTREAM	CpG: 53	Hypermethylated